Media Room

 

 

Latest News Releases
Sep 12, 2017

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and safety of NKTR-214, the company's lead immuno-oncology...

Sep 6, 2017

Nektar Therapeutics (Nasdaq: NKTR) today presented clinical data from the SUMMIT-07 Phase 3 study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain, at the 2017 PAINWeek®...

Sep 6, 2017

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan Stanley Global Healthcare Conference in New York...

More »

Multimedia Libraries
Media Contacts
Dan Budwick
Pure Communications, Inc.
Media@purecommunications...

More »

Follow Us on LinkedIn
Follow Us on Twitter


print email
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide